Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RSV Corporation
Minato-ku, Tokyo, Japanrsv-corp.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
RSV Corporation is a clinical-stage biotechnology company based in Japan that specializes in the development of innovative antiviral therapies for Respiratory Syncytial Virus (RSV). Founded as a spin-off from the Institute of Medical Science at the University of Tokyo, the company focuses on addressing the high unmet medical need for effective RSV treatments in infants and the elderly. Its lead candidate, RSVC-001, is an orally bioavailable small molecule inhibitor designed to prevent viral entry by targeting the RSV fusion protein. The company aims to provide a safe and effective treatment option to reduce the global burden of RSV-related hospitalizations and severe respiratory disease.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on RSV Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV Corporation.